XERS - Regeneron in research agreement with Xeris Biopharma

2023-03-30 07:17:56 ET

• Xeris Biopharma Holdings ( NASDAQ: XERS ) announced Thursday an agreement with Regeneron Pharmaceuticals ( REGN ) to use its drug-formulation platform, XeriJect, to develop monoclonal antibodies for subcutaneous delivery.
• Per the terms, Chicago, Illinois-based Xeris ( XERS ) will utilize its XeriJect platform to develop ready-to-use, small-volume subcutaneous injections of two undisclosed monoclonal antibodies developed by Regeneron ( REGN ).
• Regeneron ( REGN ) will have the option to license the Xeris technology for those molecules and select additional molecules for potential commercialization.
• In return, the company will be entitled to an upfront payment and potential milestone payments for pre-clinical work. The exact financial terms of the transaction were not disclosed.
• Read: Seeking Alpha contributor Jonathan Faison issued a Buy rating on Xeris ( XERS ) early this week, arguing that the company is a picks-and-shovels play in biopharma with long-term potential.

For further details see: